Navigation Links
Spherix Postpones 2009 Annual Shareholders Meeting to Share Interim Diabetes Clinical Trial Data
Date:3/11/2009

INTERIM DATA FROM PHASE 3 CLINICAL TRIAL FOR NATURLOSE(R) ANTICIPATED BY FALL

BETHESDA, Md., March 11 /PRNewswire-FirstCall/ -- Spherix Incorporated (Nasdaq: SPEX), an innovator in biotechnology and a provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced the postponement of its 2009 Annual Shareholders Meeting. Previously scheduled for May, the meeting will instead be held during the Fall of 2009, when it is anticipated that interim data from its pivotal Phase 3 clinical trial of Naturlose as a drug for Type 2 diabetes will be available.

The Company's Board of Directors, based on the recommendation of its senior management team, has decided to hold the meeting in early Fall so that an interim analysis of the data from the Company's Phase 3 trial can be shared with Spherix's shareholders. The date for the meeting will be set based on the Company's early analysis of the trial data. The trial is currently on schedule, and Spherix expects to have enough patients by the end of the second quarter to perform the interim analysis, with the results expected to be ready to be presented at a meeting later this year.

Dr. Claire Kruger, Chief Executive Officer of Spherix, said, "Postponing this year's Annual Shareholders Meeting until we are able to share the results of the interim analysis with our shareholders is a logical decision for us. We believe this will be a significant moment for both Spherix and its shareholders, and we are enthusiastic about the trial's potential to demonstrate the efficacy of Naturlose as a treatment for Type 2 diabetes."

About Spherix

Spherix Incorporated was launched in 1967 as a scientific research company, under the name Biospherics Research. The company now leverages its scientific and technical expertise and experience through its two subsidiaries -- Biospherics Incorporated and Spherix Consulting, Inc. Biospherics is currently running a Phase 3 clinical trial to study the use of Naturlose as a treatment for Type 2 diabetes. Its Spherix Consulting subsidiary provides scientific and strategic support for suppliers, manufacturers, distributors and retailers of conventional foods, biotechnology-derived foods, medical foods, infant formulas, food ingredients, dietary supplements, food contact substances, pharmaceuticals, medical devices, consumer products, and industrial chemicals and pesticides. For more information, please visit www.spherix.com.

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of Naturlose, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our continuing efforts to develop Naturlose may be unsuccessful, our common stock could be delisted from the Nasdaq Capital Market, and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission, including our current report on Form 8-K filed on October 10, 2007. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE Spherix Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Spherix Reports Second Quarter Earnings
2. Growth Achieved in Spherixs Health Sciences Consulting Business
3. Spherix D-tagatose to be Supplied by Inalco SpA
4. Spherix Expands Phase 3 Naturlose Diabetes Trial Outside of the U.S.
5. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
6. The First Annual Cervical Cancer/HPV Conference Tackles Controversial Vaccine Issues and Encourages Advocacy
7. Oculus Innovative Sciences to Present at 4th Annual BIO InvestorForum Conference
8. New MIRCERA(R) Data Analyses to be Featured at the American Society of Nephrology Annual Meeting
9. Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
10. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
11. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... January 18, 2017 According to a new report published ... Global Opportunity Analysis and Industry Forecast, 2014 - 2022," the global polyphenol market ... million by 2022, growing at a CAGR of 8.26% from 2016 to 2022. ... revenue. Continue Reading ... ...
(Date:1/18/2017)... Jan. 18, 2017 Safe Rx LLC and ... based in Loveland, Colorado , today ... in selected Good Day locations.     "Patients ... alternative for secure storage," said Milton Cohen , ... the price of a cup of coffee, you can ...
(Date:1/18/2017)... 18, 2017   Seno Medical Instruments, Inc. , ... cancer through the development of an opto-acoustic (OA/US) imaging ... as SVP of Engineering. Mr. Miller previously served ... SonoSite, with headquarters in Bothell, Washington ... 30-year career to the development of innovative medical imaging ...
Breaking Medicine Technology:
(Date:1/18/2017)... , ... January 18, 2017 , ... From a health ... released almost daily linking gut health to chronic disease, mental health and general physical ... ” as an important resolution to consider. , For one Charlottesville restaurant, good gut ...
(Date:1/18/2017)... ... January 18, 2017 , ... The V Foundation for Cancer Research, a top-rated ... training and fundraising team, to compete in the Boston Marathon on April 17. ... the world’s oldest annual marathon to join Team V and support the Foundation’s mission ...
(Date:1/18/2017)... (PRWEB) , ... January 18, 2017 , ... At Hallmark ... to announce that they have achieved certification to ISO 13485. This certification is another ... most up to date products and services that they need. , The ISO 13485 ...
(Date:1/18/2017)... ... 18, 2017 , ... Rollerblade®, the worldwide leader in inline ... braking system that allows skaters of all levels to stop safely with more ... of beginner and intermediate skaters – learning how to brake with more balance ...
(Date:1/17/2017)... ... ... Gym Source, America’s leading retailer of premium residential and commercial fitness equipment, ... FL. , “We are elated to be opening this new showroom,” explains Tom Richard, ... give clients a seamless and motivating shopping experience.” , Every fitness journey is unique, ...
Breaking Medicine News(10 mins):